TB4-FRAG is a fragment of thymosin beta-4, a peptide found naturally in the body's tissue-repair secretions, investigated for wound healing and anti-inflammatory effects.
What it does
TB4-FRAG refers to peptide fragments derived from thymosin beta-4 (Tβ4), a small signaling protein involved in cytoskeletal regulation — meaning it helps control the internal scaffolding that gives cells their shape and mobility. Full-length Tβ4 works partly by sequestering G-actin (the free, unpolymerized form of actin), which influences how cells migrate and repair damaged tissue PubMed 15466884. The fragments studied here are shorter segments of that parent molecule, identified in the secretome (the full collection of proteins and peptides a cell secretes) of human amniotic mesenchymal stromal cells (hAMSCs) — stem-like cells derived from the inner membrane of the placenta PubMed 39448028.
Those hAMSC-derived fragments, along with fragments of collagen chains and metabolic enzymes, appear in the sub-10 kDa fraction of the secretome — the lightweight end of the molecular weight spectrum. They have been linked to wound healing, anti-inflammatory signaling, and tissue regeneration, though the precise mechanisms of the fragments themselves (as distinct from full-length Tβ4) are not yet well characterized PubMed 39448028. Separately, Tβ4-derived peptides have been shown to stimulate angiogenesis (the formation of new blood vessels), which accelerates tissue repair by improving local blood supply PubMed 21872226. One well-studied fragment, AcSDKP, derived from the N-terminal end of Tβ4, also modulates mast cell activity and influences local immune responses PubMed 17191900.
What the evidence shows
Wound healing and tissue repair Strong rodent and in vitro evidence; very limited direct human data for the fragment specifically
Tβ4-derived peptides have demonstrated pro-angiogenic effects both in cell culture and in animal models, supporting faster tissue repair by promoting new blood vessel growth into injured areas PubMed 21872226. Tβ4 fragments have been detected in the secretome of wound-site fluid in vivo, identified using capillary ultrafiltration probes and mass spectrometry in animal wound models, suggesting they are produced naturally during healing PubMed 17001601. The identification of these same fragments in the hAMSC secretome adds biological plausibility to their repair role PubMed 39448028, but controlled human trials specifically on TB4-FRAG as an administered peptide do not yet exist in the published literature.
Anti-inflammatory and immune modulation Mechanistic and in vitro evidence; human data absent for the fragment form
The N-terminal Tβ4 fragment AcSDKP inhibits mast cell proliferation and degranulation — processes that drive local inflammation — in vitro PubMed 17191900. Because TB4-FRAG encompasses peptide segments of this parent molecule, similar modulatory effects are theoretically plausible. However, no clinical trials have tested TB4-FRAG as a standalone anti-inflammatory agent in humans, so this remains a mechanism-based inference rather than a demonstrated outcome.
How it's used
There is no established clinical dosing protocol for TB4-FRAG in the published literature. No standardized route, dose, frequency, or timing has been validated in human trials. In the research context, Tβ4-derived peptides have been studied in subcutaneous and topical formats in animal models, but these findings have not been translated into confirmed human protocols. Any self-reported use appears to follow loose extrapolations from full-length thymosin beta-4 protocols, which themselves vary widely. Given the absence of pharmacokinetic data — including half-life — for TB4-FRAG specifically, no dosing guidance can be responsibly offered here.
Side effects and safety
Reported side effects in the context of Tβ4-class peptides include mild injection site reactions, transient headache, and fatigue. These are self-reported and not systematically documented in controlled trials for TB4-FRAG specifically. The more significant concern is theoretical: because Tβ4-derived peptides promote angiogenesis, there is a plausible risk that they could support tumor vascularization in individuals with active or occult malignancy. This risk has not been quantified in human studies but is serious enough to treat as an absolute contraindication. Long-term safety data — on duration of use, cumulative dose effects, or interactions with other compounds — do not exist. Pregnancy is also contraindicated given the peptide's activity in cell proliferation and tissue remodeling pathways during a period of tightly regulated fetal development.
Bottom line
TB4-FRAG has a biologically coherent mechanism and shows promise in preclinical wound-healing and angiogenesis research, but human trial data for this specific fragment are essentially nonexistent. People with active cancer or who are pregnant should not use it. For everyone else, the evidence base is thin enough that this remains an experimental compound in the truest sense.